A Systematic Review and Meta-Analysis of the Efficacy and Safety of Rasagiline or Pramipexole in the Treatment of Early Parkinson’s Disease

Table 1

The main characteristics of the rasagiline studies included in the systematic review.

Study, year	Intervention	Dose (mg/day)	Duration (wk.)	Population (n)	Number of withdrawals	Mean age (yr.)	Males (%)	Duration of PD (yr.)	H&Y stage	Country	Other PD medications in entire population (%)
Barone et al. 2015	RA vs. PBO	1	12	65	8	66.1 ± 8.4	58.5	4.8 ± 3.8	1.9 ± 0.5	Italy	LD (65.8), LD + CD + EC (15.4), Me-LD (8.9), RR (13.8), PPX (40.1), RG (6.5), EC (1.6)
				58	9	66.0 ± 8.7	46.6	3.7 ± 3.2	1.8 ± 0.5
Hanagasi et al. 2011	RA vs. PBO	1	12	25	7 (PBO + RA)^a	67.6 ± 10.1	64.0	4.0 ± 2.3	1.6 ± 0.6	Turkey	LD and derivatives (91.7), DAA (54.2)
				23; 7 (dropouts)		65.2 ± 9.5	73.9	4.1 ± 2.5	2.0 ± 0.7
Hattori et al. 2019	RA vs. PBO	1	26	126	26	65.4 ± 8.8	42.9	1.6 ± 1.2	2.2 ± 0.6	Japan	Other PD medications were discontinued >30 day before the study
				118	8	67.4 ± 9.0	44.9	2.0 ± 2.0	2.2 ± 0.6
Hauser et al. 2014^b	RA vs. PBO	1	18	165	20	62.8 ± 10.1	68.5	2.1 ± 1.9	≤3	United States	DAA (100) (PPX (58.6), RR (41.4)), AM (6.7), AC (3.7), rescue LD (3.4)
				163	20	62.3 ± 9.3	67.9	2.2 ± 2.2	≤3
Olanow et al. 2009	RA vs. PBO	1, 2	72	595^d	50^e	62.2 ± 9.7	61.8	4.4 ± 4.6 mo.	1.5 ± 0.5	14 countries	The study included only subjects who were not receiving any PD treatment
Rascol et al. 2011^c				288; 293	15; 20	62.4 ± 9.7; 62.3 ± 9.6	60.8; 59.7	4.6 ± 4.7 mo.; 4.6 ± 4.6 mo.	1.5 ± 0.5; 1.5 ± 0.5
Schrempf et al. 2018	RA vs. PBO	1	8	10	3	70.2 ± 7.3	60.0	3.3 ± 3.5	2.3 ± 0.8	Germany	LD (53.3), DAA (60.0), COMT-I (3.3)
				20	2	69.9 ± 6.9	50.0	4.0 ± 3.5	1.9 ± 0.8
Stern et al. 2004	RA vs. PBO	1, 2, 4	10	13	0	64.8 ± 9.4	76.9	0.8 ± 1.0	1.5 ± 0.4	United States	Other PD drugs not permitted
				15	1	59.3 ± 8.6	66.7	1.3 ± 2.6^f	1.5 ± 0.4
				14	0	60.3 ± 7.2	71.4	0.4 ± 0.8	1.6 ± 0.4
				14	0	62.0 ± 9.7	57.1	0.3 ± 0.5	1.6 ± 0.4
Viallet et al. 2013	PPX vs. RA	1.5	15	56	14	62.1 ± 6.2	55.4	4.3 ± 7.3 mo.	≤3^g	France	All PD treatments were discontinued
		1		53	3	63.2 ± 7.3	69.8	2.5 ± 3.8 mo.	≤3^g

Values are reported as mean ± standard deviation. CD = carbidopa, DAA = dopamine agonists, EC = entacapone, mo = months, PBO = placebo, PD = Parkinson’s disease, PPX = pramipexole, RA = rasagiline, RCT = randomized controlled trial, RG = rotigotine, RR = ropinirole, AC = anticholinergics, AM = amantadine, COMT-I = Catechol-O-methyl transferase inhibitors, LD = levodopa, MAOB-I = monoamine oxidase B inhibitors, wk = weeks, yr = years, and H&Y stage = Hoehn and Yahr stage. ^aWithdrawals were due to noncompliance. ^bRasagiline as add-on therapy to dopamine agonists in patients with early PD. ^cPost hoc analysis of the ADAGIO study [24]. ^dDelayed-start rasagiline 1 mg and 2 mg groups are combined as one because the treatment was in both placebo and we extracted data from week 36. ^eWithdrawals reported before starting active treatment at 36 weeks. ^fOne patient was reported as having a disease duration of 10 years. ^g94% of study subjects had a Hoehn and Yahr stage of ≤2.